rAAV-LK gene therapy (Mogam)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamerAAV-LK gene therapy (Mogam)

Drug Alias Nameoncolytic adeno-associated virus therapy encoding apolipoprotein A kringles LK68 and LK8 (Mogam/GC Pharma)rAAV-LK gene therapy (Mogam/Green Cross)rAAV-LK68rAAV-LK8MG-1110

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionImmunostimulantsAngiogenesis inhibitors

TargetsUpdating

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMogam Biotechnology Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMogam Biotechnology Institute GC Biopharma Corp

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A